Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1658 1676
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18265368 | USE OF SYNTHETIC COPOLYPEPTIDE HYDROGELS AS DERMAL FILLERS | Non-Final OA | The Regents of the University of California |
| 16082924 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR IMPROVED DRUG LOADING | Final Rejection | The Regents Of The University of California |
| 18238261 | COMPOSITIONS AND METHODS FOR TREATING TYPE 2 DIABETES USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 16633701 | COMPOUND AND METHOD FOR PRODUCING THE SAME | Final Rejection | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION |
| 18365648 | GENETICALLY ENGINEERED RECOMBINANT PROTEINS FOR FUNCTIONAL REGENERATIVE TISSUE SCAFFOLDS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18783546 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Non-Final OA | Mallinckrodt Pharmaceuticals Ireland Limited |
| 17104864 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Final Rejection | Mallinckrodt Pharmaceuticals Ireland Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy